An interventional study of sodium Chloride and Ropivacaine 0.2% Injectable Solution in Hip Osteoarthritis, sponsored by Poznan University of Medical Sciences. Completed at 1 site in Poland. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Poznan University of Medical Sciences · Not applicable, Interventional, and Treatment
Among 13 studies testing ropivacaine in Osteoarthritis, Hip — 3 open to participants now, 3 under way, none of them phase 3. Ropivacaine · Osteoarthritis, Hip.
Among the 13 studies testing ropivacaine in Osteoarthritis, Hip, this one is the 9th largest by enrollment, is one of 3 that started in 2026, is one of 3 with no phase, and was the 11th registered.
641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
This study's enrollment of 60 is below the median of 90 across 457 interventional studies indexed under Osteoarthritis, Hip.
Browse Osteoarthritis, Hip studies →3 of the 13 studies testing ropivacaine in Osteoarthritis, Hip are open now, in 1 country. Each count lists the studies.
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 65 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →13 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2026.
Median enrollment 90 across the 13 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
None of the 13 has an industry lead sponsor. The 6 most frequent:
Poznan University of Medical Sciences is the lead sponsor of 151 studies on the registry; 41 are open to participants now.
21 studies in Osteoarthritis, Hip by Poznan University of Medical Sciences: 9 open now, 9 under way, none of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 21 studies in Osteoarthritis, Hip by Poznan University of Medical Sciences, this one is the 15th largest by enrollment, is one of 10 that started in 2026, is one of 10 with no phase, and was the 17th registered.
Poznan University of Medical Sciences’s Osteoarthritis, Hip studies by the year they started, since 2020.
2 of the studies testing ropivacaine in Osteoarthritis, Hip that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449468Poznan University of Medical SciencesPENG Block and Delirium After Hip Arthroplasty | 2027-05-01 |
| NCT07180979Poznan University of Medical SciencesPENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty | 2027-09-30 |
Among the 13 studies testing ropivacaine in Osteoarthritis, Hip, from their registry updates:
Among Poznan University of Medical Sciences’s 21 in Osteoarthritis, Hip:
This randomized controlled trial evaluates the effect of ultrasound-guided Pericapsular Nerve Group (PENG) block on the Systemic Inflammation Response Index (SIRI) in elderly patients undergoing total hip arthroplasty under spinal anesthesia. SIRI, calculated as neutrophil count × monocyte count / lymphocyte count, is used as a composite marker of perioperative inflammatory response. The study investigates whether PENG block attenuates the systemic inflammatory reaction to surgical trauma compared to sham block. The study investigates whether PENG block attenuates the systemic inflammatory reaction to surgical trauma compared to sham block.
Surgical trauma induces a systemic inflammatory response characterized by neutrophilia, lymphopenia, and platelet activation. These hematologic alterations reflect the interaction between innate immune activation, stress-induced immunosuppression, and pro-thrombotic mechanisms. The modulation of this response may influence postoperative recovery and complication risk.
The Systemic Inflammation Response Index (SIRI) is calculated as neutrophil count × monocyte count / lymphocyte count. It incorporates neutrophils and monocytes in relation to lymphocytes as a composite marker of systemic inflammation. This study evaluates whether PENG block influences postoperative SIRI in patients undergoing total hip arthroplasty.
The primary objective of this study is to compare SIRI at 12 hours after surgery between the PENG block and sham block groups in elderly patients undergoing total hip arthroplasty under spinal anesthesia.
Peripheral venous blood samples will be collected preoperatively and at 12, 24, and 48 hours after surgery. The primary endpoint is SIRI at 12 hours after surgery.
This study aims to determine whether motor-sparing regional anesthesia may modulate systemic inflammatory response beyond analgesic effects, potentially contributing to improved perioperative outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PENG block with 20ml of 0.9% sodium chloride
Drug: sodium Chloride
PENG block with 20ml 0f 0.2% ropivacaine
Drug: Ropivacaine 0.2% Injectable Solution
After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20ml of 0.9% sodium chloride
Also known as: 0.9% Sodium Chloride Injection
After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20 ml of 0.2% ropivacaine
Also known as: 0.2% ropivacaine
Systemic Inflammation Response Index (SIRI)
Systemic Inflammation Response Index (SIRI) is used as a composite marker of systemic inflammatory activation. It is calculated from peripheral venous blood samples using the formula: SIRI = (Neutrophil count × Monocyte count) / Lymphocyte count All parameters are obtained from routine complete blood count (CBC) analysis and expressed in ×10⁹/L. SIRI reflects the interaction between innate immune activation (neutrophils and monocytes) and adaptive immune suppression (lymphocytes). Higher SIRI values indicate greater systemic inflammatory response.
Time frame: 12 hours after surgery
Systemic Inflammation Response Index (SIRI)
Systemic Inflammation Response Index (SIRI) is used as a composite marker of systemic inflammatory activation. It is calculated from peripheral venous blood samples using the formula: SIRI = (Neutrophil count × Monocyte count) / Lymphocyte count All parameters are obtained from routine complete blood count (CBC) analysis and expressed in ×10⁹/L. SIRI reflects the interaction between innate immune activation (neutrophils and monocytes) and adaptive immune suppression (lymphocytes). Higher SIRI values indicate greater systemic inflammatory response.
Time frame: 24 hours after surgery
Systemic Inflammation Response Index (SIRI)
Systemic Inflammation Response Index (SIRI) is used as a composite marker of systemic inflammatory activation. It is calculated from peripheral venous blood samples using the formula: SIRI = (Neutrophil count × Monocyte count) / Lymphocyte count All parameters are obtained from routine complete blood count (CBC) analysis and expressed in ×10⁹/L. SIRI reflects the interaction between innate immune activation (neutrophils and monocytes) and adaptive immune suppression (lymphocytes). Higher SIRI values indicate greater systemic inflammatory response.
Time frame: 48 hours after surgery
Aggregate Index of Systemic Inflammation (AISI)
Aggregate Index of Systemic Inflammation (AISI) is calculated as: AISI = (Neutrophil count × Monocyte count × Platelet count) / Lymphocyte count All values are obtained from routine CBC and expressed in ×10⁹/L. AISI integrates neutrophils, monocytes, platelets, and lymphocytes, providing a broader assessment of systemic inflammatory and immune response compared to single ratios.
Time frame: 12 hours after surgery
Aggregate Index of Systemic Inflammation (AISI)
Aggregate Index of Systemic Inflammation (AISI) is calculated as: AISI = (Neutrophil count × Monocyte count × Platelet count) / Lymphocyte count All values are obtained from routine CBC and expressed in ×10⁹/L. AISI integrates neutrophils, monocytes, platelets, and lymphocytes, providing a broader assessment of systemic inflammatory and immune response compared to single ratios.
Time frame: 24 hours after surgery
Aggregate Index of Systemic Inflammation (AISI)
Aggregate Index of Systemic Inflammation (AISI) is calculated as: AISI = (Neutrophil count × Monocyte count × Platelet count) / Lymphocyte count All values are obtained from routine CBC and expressed in ×10⁹/L. AISI integrates neutrophils, monocytes, platelets, and lymphocytes, providing a broader assessment of systemic inflammatory and immune response compared to single ratios.
Time frame: 48 hours after surgery
Platelet Mass Index (PMI)
Platelet Mass Index (PMI) reflects total circulating platelet mass and is calculated as: PMI = Platelet count × Mean Platelet Volume (MPV) Platelet count is expressed in ×10⁹/L and MPV in femtoliters (fL). PMI reflects platelet activation and thrombo-inflammatory potential, which may increase in response to surgical stress.
Time frame: 12 hours after surgery
Platelet Mass Index (PMI)
Platelet Mass Index (PMI) reflects total circulating platelet mass and is calculated as: PMI = Platelet count × Mean Platelet Volume (MPV) Platelet count is expressed in ×10⁹/L and MPV in femtoliters (fL). PMI reflects platelet activation and thrombo-inflammatory potential, which may increase in response to surgical stress.
Time frame: 24 hours after surgery
Platelet Mass Index (PMI)
Platelet Mass Index (PMI) reflects total circulating platelet mass and is calculated as: PMI = Platelet count × Mean Platelet Volume (MPV) Platelet count is expressed in ×10⁹/L and MPV in femtoliters (fL). PMI reflects platelet activation and thrombo-inflammatory potential, which may increase in response to surgical stress.
Time frame: 48 hours after surgery
C-reactive Protein (CRP) Concentration
C-reactive protein (CRP) is a laboratory marker of acute systemic inflammation measured in peripheral venous blood samples. CRP concentration is expressed in mg/L and determined using standard hospital laboratory methods. Higher CRP values indicate greater postoperative inflammatory response.
Time frame: 12 hours after surgery
C-reactive Protein (CRP) Concentration
C-reactive protein (CRP) is a laboratory marker of acute systemic inflammation measured in peripheral venous blood samples. CRP concentration is expressed in mg/L and determined using standard hospital laboratory methods. Higher CRP values indicate greater postoperative inflammatory response.
Time frame: 24 hours after surgery
C-reactive Protein (CRP) Concentration
C-reactive protein (CRP) is a laboratory marker of acute systemic inflammation measured in peripheral venous blood samples. CRP concentration is expressed in mg/L and determined using standard hospital laboratory methods. Higher CRP values indicate greater postoperative inflammatory response.
Time frame: 48 hours after surgery
Postoperative Pain Intensity (NRS)
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 to 10, where: 0 = no pain 10 = worst pain imaginable Pain scores will be recorded at rest.
Time frame: 4 hours after surgery
Postoperative Pain Intensity (NRS)
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 to 10, where: 0 = no pain 10 = worst pain imaginable Pain scores will be recorded at rest.
Time frame: 8 hours after surgery
Postoperative Pain Intensity (NRS)
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 to 10, where: 0 = no pain 10 = worst pain imaginable Pain scores will be recorded at rest.
Time frame: 12 hours after surgery
Postoperative Pain Intensity (NRS)
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 to 10, where: 0 = no pain 10 = worst pain imaginable Pain scores will be recorded at rest.
Time frame: 24 hours after surgery
Postoperative Pain Intensity (NRS)
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 to 10, where: 0 = no pain 10 = worst pain imaginable Pain scores will be recorded at rest.
Time frame: 48 hours after surgery
Opioid Consumption
Total opioid consumption within the first 48 hours after surgery will be recorded. All administered opioids will be converted to intravenous morphine milligram equivalents (MME) for standardization. Higher cumulative MME indicates greater analgesic requirement.
Time frame: 48 hours after surgery
Time to First Rescue Analgesia
Time from completion of surgery to first administration of rescue opioid analgesia. Measured in minutes. Shorter time indicates earlier breakthrough pain.
Time frame: 48 hours after surgery
Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in publications (including demographic data, laboratory inflammatory indices such as SII, SIRI, AISI, CRP values, pain scores, opioid consumption, and time-to-event outcomes) will be made available to qualified researchers. Data will be shared after removal of all direct identifiers in accordance with GDPR regulations and institutional data protection policies. The study protocol, statistical analysis plan (SAP), and analytic code will also be available upon reasonable request. Data will be provided for the purpose of secondary analyses, meta-analyses, or validation studies, subject to approval by the principal investigator and institutional review board, where applicable.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will become available 6 months after publication of the primary results and will remain available for 5 years.
Access criteria: Access will be granted to researchers who provide: A methodologically sound research proposal Institutional affiliation Ethical approval (if required) A signed data use agreement Requests should be directed to the principal investigator via institutional email.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Poznan University of Medical Sciences →